First FDA Approval: Combination Therapy for Rare Childhood Cancer, Neuroblastoma
Name
Excellence in Technology Transfer
From
Federal Laboratory Consortium (FLC)
Type
Mid-Atlantic Region Award
Year
2015
ICs
NCI
Applications
Therapeutics